Everolimus is a type of medication known as a mammalian target of rapamycin (mTOR) inhibitor, which is used to treat certain types of cancer and prevent organ rejection in transplant patients. It works by blocking the activity of the mTOR protein, which plays a key role in cell growth and division. Research in the field of everolimus is focused on further understanding its mechanisms of action, identifying potential new applications for the drug, and optimizing its use in different patient populations. This includes studying the drug's effectiveness in treating different types of cancer, exploring potential combination therapies, and investigating ways to minimize side effects. Overall, research on everolimus aims to improve treatment options for cancer patients and transplant recipients, ultimately leading to better outcomes and quality of life for these individuals.